.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually submitted to debut on the general public market.The Eli Lilly-partnered biotech plan to detail on the Nasdaq under the symbol “BIOA,” according to documentations submitted along with the Securities and Substitution Commission. The business has actually certainly not openly discussed an expected financial amount for the offering.The clinical-stage business boasts lead candidate azelaprag, a by mouth provided small molecule slated to enter into stage 2 testing in combination along with semaglutide– sold through Novo Nordisk under trademark name Wegovy for weight reduction– in the 1st one-half of upcoming year. Semaglutide is actually likewise sold as Ozempic and also Rybelsus by Novo for diabetic issues.
Apelin receptor agonist azelaprag is made to integrate well along with GLP-1 medicines, improving effective weight loss while protecting muscle mass. The investigational drug was located to be well-tolerated one of 265 individuals all over eight period 1 trials, depending on to BioAge.Recently, BioAge amassed the assistance of Lilly to run a test integrating azelaprag with the Significant Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetes mellitus as Mounjaro and also Zepbound for fat loss. The companions are presently carrying out a stage 2 trial of azelaprag as well as tirzepatide, along with topline outcomes expected in the third fourth of 2025.The biotech is actually also organizing an insulin level of sensitivity proof-of-concept test examining azelaprag as a monotherapy in the initial fifty percent of following year to support prospective evidence development.
Furthermore, the business considers to talk to the FDA for approval in the second fifty percent of 2025 to release human testing for an NLRP3 inhibitor targeting metabolic diseases and neuroinflammation.BioAge’s expected transfer to the general public market observes a slight uptick in considered biotech IPOs from Bicara Therapies and also Zenas Biopharma. Zooming out, the recent IPO landscape is a “mixed image,” along with high-quality business still debuting on everyone markets, only in reduced varieties, depending on to PitchBook.